Drugs / YRA-1909
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03275025 | Apr 2017 → Nov 2019 | rheumatoid arthritis | Yungjin Pharm. Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-01-07 | NovaCell Technology Inc. | Regulatory 노바셀, 류마티스관절염 치료제 국내 임상 2상 돌입 novacelltech.com ↗
노바셀테크놀로지(대표이사 이태훈)는 영진약품과 공동 개발 중인 류마티스관절염 치료제 "YRA-1909"에 대해 식품의약품안전처로부터 2015년 12월 31일자로 임상 2상 시험 승인을 받았다고 밝혔다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-01-07 | NovaCell Technology Inc. | 노바셀, 류마티스관절염 치료제 국내 임상 2상 돌입 novacelltech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YRA-1909 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03275025 ↗ |
| Route | Oral | “daily oral intake” NCT03275025 ↗ |